Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) had Return on Equity of -335.50% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.31M |
|
$-8.31M |
|
$3.96M |
|
$-2.65M |
|
$8.85M |
|
$-7.54M |
|
$-0.77M |
|
$-8.31M |
|
$-8.31M |
|
$-8.31M |
|
$-8.31M |
|
$-8.31M |
|
$-8.31M |
|
$-7.54M |
|
$-6.12M |
|
2.33M |
|
2.33M |
|
$-3.60 |
|
$-3.60 |
|
| Balance Sheet Financials | |
$2.05M |
|
$7.79M |
|
$9.57M |
|
$11.63M |
|
$1.58M |
|
$0.29M |
|
$1.94M |
|
$3.52M |
|
$2.48M |
|
$8.10M |
|
$8.10M |
|
3.47M |
|
| Cash Flow Statement Financials | |
$-6.03M |
|
$-0.02M |
|
$5.77M |
|
$2.10M |
|
$1.81M |
|
$-0.28M |
|
$0.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.30 |
|
-- |
|
-- |
|
0.04 |
|
0.04 |
|
-202.29% |
|
-575.29% |
|
-575.29% |
|
-466.90% |
|
-633.64% |
|
-633.64% |
|
$-6.05M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
-- |
|
5.40 |
|
67.65 |
|
|
Return on Equity |
-335.50% |
-102.52% |
|
-71.45% |
|
-98.93% |
|
$2.34 |
|
$-2.59 |
|
$-2.58 |
|